Fact CheckerSign in

NCT06798220Completed

Ultra-Processed Foods and Appetite Regulation: Acute Effects Across Body Mass Index Categories

Acute Effects of Ultra-processed Foods on Appetite Regulation in Individuals with Different Body Mass Indexes

Source: ClinicalTrials.gov · Last updated 31 Jan 2025

Brief summary (registry, in English)

This study was planned to observe the acute effects of minimally processed and ultra-processed food (UPF) consumption on appetite in participants with normal body mass index (BMI) \[BMI: 18.5-24.99 kg/m2\] and overweight-obese (BMI \> 25 kg/m2) according to the NOVA (not an abbreviation) classification and to compare the postprandial effects of minimally processed and UPF consumption on appetite in normal and overweight-obese individuals. The study was designed as a non-randomized controlled, crossover study. The main questions it aims to answer are: * Does a breakfast consisting of UPF affect appetite regulation differently compared to a breakfast consisting of unprocessed or minimally processed foods? * Do the effects of foods with different levels of processing on appetite regulation vary by BMI? Researchers will evaluate the effects of a breakfast containing unprocessed or minimally processed foods and a breakfast containing ultra-processed foods, which are similar in terms of energy and macronutrients, on appetite regulation. Participants will: * 1st experiment day: come to the laboratory where the experiment will be conducted at 8:00 am on an empty stomach and consume a breakfast containing unprocessed or minimally processed foods (chicken egg (boiled), white cheese (full-fat), black and green olive, tomato, cucumber, white bread, orange juice (freshly squeezed). * 2nd experiment (after 2 weeks wash-out from 1st experiment): come to the laboratory where the experiment will be conducted at 8:00 am on an empty stomach and consume a breakfast containing ultra-processed food (packaged sandwich bread, beef sausage (pan-fried without oil), tomato ketchup, packaged orange juice).

Status (registry)
Completed
Study type
Interventional
Enrollment
28 (actual)
First submitted
23 Jan 2025
Start date
1 May 2024
Primary completion date
30 Jul 2024
Lead sponsor
Ondokuz Mayıs University
Diseases
Obesity
NCT number
NCT06798220

What you commit to

  • Study type: Interventional
  • Participants enrolled: 28
  • From 1 May 2024 to the primary completion date, 30 Jul 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Undergoing hormone replacement therapy
  • Taking regular medication (such as hormone replacement therapy, anticoagulants, antidepressants, antidiabetics, antihypertensives, antihyperlipidemics, proton pump inhibitors, etc.)

Other illness

  • Having an acute or chronic illness
  • Having a genetic and/or systemic disease
  • Having any food allergies or intolerances

Other

  • Being pregnant, breastfeeding, or postmenopausal
  • Being in the premenstrual or menstruation phase
  • Following a specific dietary regimen
  • Smoking
  • Consuming alcohol
  • Having used antibiotics in the last 3 months
  • Using prebiotics or probiotics
  • Not giving consent after reading the informed consent form

Who the study is looking for

  • Body mass index between 18.50-24.99 kg/m2 or \> 25.00 kg/m2
  • Not in premenstrual (1 week before menstruation) period or menstrual period for women participants

Age in the registry: 19 years to 40 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Ondokuz Mayıs University Kurupelit Campus, 55139 Atakum / SAMSUN
Coordinator of this site? Confirm its status
SamsunTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.